Levofloxacin is a prescription antibiotic, and people who are taking it ahead of a scheduled workplace drug test sometimes want to know whether it could affect their result. This post looks at what levofloxacin is, whether it is a controlled substance, what published literature actually says about cross reactivity with opiate immunoassay screens, and what happens procedurally if a screen comes back presumptive positive while someone is on this medication.
What levofloxacin is and how it is classified
Levofloxacin is a fluoroquinolone antibacterial, a class of antibiotics used to treat bacterial infections such as pneumonia, urinary tract infections, and chronic bacterial prostatitis. According to its prescribing label on DailyMed, levofloxacin is a human prescription drug and is not scheduled as a controlled substance. It does not appear on any Drug Enforcement Administration controlled substance schedule, and it has no abuse potential in the way that opioids or stimulants do.
Antibiotics as a group are a common question for this reason; a related post looks at how amoxicillin interacts with cocaine screens, which is a different mechanism on a different panel. That distinction matters for drug testing purposes. A medication being prescription only is a separate question from whether a standard immunoassay panel is designed to detect it, or whether it can interfere with a panel that is screening for something else entirely.
Is levofloxacin part of any standard drug test panel
No. Levofloxacin is not a target analyte on any standard 5, 10, or 12 panel immunoassay. Workplace and clinical urine panels are built to screen for classes such as amphetamines, cocaine metabolite, opiates, phencyclidine (PCP), tetrahydrocannabinol (THC), and depending on the panel, benzodiazepines, barbiturates, methadone, propoxyphene, and MDMA. An antibiotic like levofloxacin is not one of the substances these assays are designed to flag, and no laboratory panel reports an antibiotic as its own result line.
The relevant question is not whether levofloxacin shows up as its own finding. It is whether taking levofloxacin can trigger a false positive on an unrelated panel, specifically the opiate screen.
What the published evidence says about opiate cross reactivity
This is where levofloxacin is genuinely different from most antibiotics covered in this series. There is a documented, published case report describing exactly this interference. A case report in the Canadian Medical Association Journal, archived on PubMed Central, describes a patient started on levofloxacin whose urine opiate immunoassay screen returned positive at a laboratory cutoff of 300 ng/mL. Confirmatory testing by mass spectrometry on both the urine and serum samples, run at much lower cutoffs, came back negative for opiates. The authors concluded that fluoroquinolones, specifically naming levofloxacin, ofloxacin, and pefloxacin, can cross react with enzyme immunoassay opiate screens and recommended that any positive screen in a patient on these antibiotics be confirmed by a nonimmunologic method before any clinical or employment decision is made.
A separate, broader review of urine drug screening for clinicians, also archived on PubMed Central, discusses immunoassay cross reactivity as a general limitation of screening technology. It explains that a false positive can occur when a structurally unrelated or "out of class" compound reacts with the antibody used in the screening assay, and it identifies fluoroquinolone antibiotic cross reactivity with opiate assays specifically as one of the documented examples. The same review emphasizes that gas chromatography and mass spectrometry (GC/MS) or liquid chromatography and mass spectrometry (LC/MS) confirmation identifies the exact drug and metabolite present and is the method that resolves a disputed screen.
Put plainly, the published evidence here is not "no published cross reactivity." For levofloxacin and the opiate immunoassay class specifically, there is a documented mechanism and a named case. That evidence is limited to opiate screens, is based on immunoassay screening technology rather than confirmation testing, and does not extend to other panel classes such as amphetamines, cocaine metabolite, THC, or PCP, where there is no comparable published finding for levofloxacin.
Panel classes with no published cross reactivity for levofloxacin
| Panel class | Published cross reactivity for levofloxacin |
|---|---|
| Opiates (morphine, codeine immunoassay) | Documented in a published case report; confirmation testing resolves it |
| Amphetamines / methamphetamine | No published cross reactivity identified |
| Cocaine metabolite | No published cross reactivity identified |
| THC (marijuana metabolite) | No published cross reactivity identified |
| PCP | No published cross reactivity identified |
| Benzodiazepines | No published cross reactivity identified |
Screening versus confirmation: why this distinction matters
An immunoassay screen, whether run on a cup, a dip card, or an oral fluid device, is a presumptive test. It uses antibodies that bind to a target drug class, and occasionally those antibodies bind to a structurally similar or, in rarer cases, a structurally unrelated compound. That is exactly the mechanism described in the levofloxacin case report. A presumptive positive on a screen is not a confirmed result and should never be treated as a final determination of drug use.
GC/MS and LC/MS confirmation testing separate and identify individual molecules with a level of specificity that immunoassay screening cannot match. In the published levofloxacin case, confirmation testing on both urine and serum was negative for morphine and codeine despite the initial immunoassay screen reading positive. This is why laboratory based drug testing programs, including those that follow federal workplace testing rules, require that every nonnegative screen be sent for confirmation before it is reported as positive.
The MRO review and prescription documentation
In programs that follow the federal workplace drug testing framework under 49 CFR Part 40, Subpart G, a laboratory confirmed positive result is never reported directly to an employer. It goes first to a Medical Review Officer, a licensed physician trained to review confirmed results and determine whether there is a legitimate medical explanation. The employee has the opportunity to provide documentation, such as a valid prescription, and the MRO decides whether that explanation accounts for the result before any verified report goes to the employer.
This process exists precisely for situations like a documented opiate cross reactivity case. Someone who is taking levofloxacin and has a nonnegative opiate screen should tell the collector or the MRO about the prescription, keep the prescription label or pharmacy documentation available, and let the confirmation test and MRO review run their course rather than assuming the result is final. Outside federally regulated programs, many employers model their own review process on the same MRO structure, though that structure is not required by law in every setting and employer policies vary.
What employers should do with a disputed result
Employers should never treat an initial immunoassay screen as a final employment decision, and should always route a nonnegative screen to confirmation testing and, where a program uses one, an MRO or equivalent qualified reviewer before taking action. If an employee discloses a prescription for levofloxacin or any other medication, that documentation should be reviewed through the same confirmation and verification process rather than dismissed. Employers should also keep in mind that state laws on how disputed or confirmed results may be used can vary, and that consulting counsel is the appropriate step for any policy question beyond the testing process itself.
For employers building or refreshing a testing program, starting with reliable point of collection devices and a confirmation pathway reduces the chance that a presumptive result like this one ever reaches a final decision without review. American Screening Corporation supplies drug test cups designed for point of collection screening as part of a broader program that should always include confirmation testing for any nonnegative result.
Frequently asked questions
Does levofloxacin show up as its own result on a drug test?
No. Levofloxacin is not a target analyte on standard 5, 10, or 12 panel immunoassay tests, and no panel reports an antibiotic as its own finding.
Can levofloxacin cause a false positive on an opiate screen?
A published case report archived on PubMed Central documents a patient on levofloxacin whose urine opiate immunoassay screen was positive while confirmatory mass spectrometry testing was negative. The authors identified fluoroquinolones, including levofloxacin, as having this cross reactivity with opiate immunoassays specifically.
Is levofloxacin a controlled substance?
No. Its official label on DailyMed lists no DEA controlled substance schedule. It is a prescription only fluoroquinolone antibiotic with no abuse potential classification.
What should someone do if they get a positive screen while taking levofloxacin?
Disclose the prescription to the collector and, in a regulated program, to the Medical Review Officer, keep pharmacy documentation available, and allow the confirmation test and MRO review to run before treating the screen as final.
Does GC/MS confirmation catch this kind of false positive?
Yes. In the published case, GC/MS confirmation at a much lower cutoff than the screening assay was negative for morphine and codeine even though the initial immunoassay screen was positive, which is exactly why confirmation testing exists.
Will levofloxacin affect other panels like THC, amphetamines, or cocaine?
There is no published cross reactivity evidence for levofloxacin on those panel classes. The documented interference is specific to opiate immunoassay screening.
This article is general information about drug testing science and procedure. It is not medical or legal advice. Anyone with questions about a specific medication or test result should talk to a qualified medical professional or a Medical Review Officer.
